|
|
|
|
|
Breaking
News
 Clinical |
|
|
|
›› Extended-duration enoxaparin thromboprophylaxis beneficial for some acutely ill medical patients – In a recent trial, extending enoxaparin prophylaxis for an additional 28 days after an initial 10-day course of therapy reduced the incidence of VTE. However, this beneficial effect was only seen in subgroups of patients with level 1 immobility, those older than 75 years, and women. Extended-duration enoxaparin was also associated with an increased risk of major bleeding events.
|
|
|
›› Delipidated HDL for acute coronary syndrome – In a first-in-man study, serial autologous delipidated HDL plasma infusions were clinically feasible and tolerated and safely increased HDL levels in patients suffering from acute coronary syndrome.
|
| |
|
 Practice |
|
|
New
Drugs
|
|
| |
|
›› Tocilizumab (Actemra—Genentech) – Recombinant, humanized monoclonal antibody for adults with moderately to severely active rheumatoid arthritis who have had inadequate response to tumor necrosis factor-alpha blockers
|
|
|
›› Telavancin (Vibativ—Astellas) – Lipoglycopeptide antibacterial agent
for treating adult patients with complicated skin and skin structure infections caused by susceptible gram-positive bacteria
|
|
|
›› Peramivir (BioCryst for CDC) – Neuraminidase inhibitor for treating specific adult and pediatric patients with suspected or laboratory-confirmed H1N1 influenza
|
|
|
|
FDA
Watch |
|
|
Educational Resources
 New Product/Therapeutics
Bulletins |
|
|
| |
|
›› New Therapeutics Bulletin: Protonix – Pantoprazole oral suspension is a new dosage form that offers clinicians an additional treatment option for the management of gastroesophageal reflux disease (GERD) and erosive esophagitis. The availability of an alternative dosage form is convenient,
and in elderly patients who may have dysphagia or for patients receiving enteral feeding, it offers a clear clinical benefit.
|
|
|
 Highlights Newsletters |
|
|
|
|
›› Parkinson’s Disease: Moving Forward With Treatment Modalities – Recent research has elucidated the
biologic underpinnings of Parkinson’s
disease (PD). It is now clear
that PD extends beyond its hallmark
motor symptoms, with nonmotor
symptoms representing the earliest signs of disease and continuing throughout the disease course. Early recognition and intervention provide an opportunity to maintain maximal function and quality of life. Advances have also been made in the development of treatments for PD and in provision of overall care.
|
| |
|
 The One Minute Counselor
|
|
|
|
›› A Pharmacist’s Guide to Fiber and Digestive Health – Fiber is associated with a number
of important health benefits, including
normal laxation. Most Americans fall far short of these recommendations. It has been estimated that the average adult consumes only 14 to 15 g of dietary fiber each day.
|
|
|
›› A Pharmacist’s Guide to the Role of Protein in Successful Weight Management – At any given time in the United States,
approximately 50% of women and 33%
of men are trying to lose weight. Excess weight usually represents an energy imbalance: more calories are being consumed than are being expended in daily activities. People who want to lose weight generally are advised to create an energy deficit of about 500 to 1,000 kcal/day, preferably through a combination of reduced calorie intake and increased physical activity.
|
|
|
›› A Pharmacist’s Guide to Food and Drug Interactions With MAO-B Inhibitors in the Treatment of Parkinson's Disease – Selective monoamine oxidase (MAO)-B
inhibitors are useful treatments for
Parkinson’s disease (PD). Selegiline and rasagiline are approved as adjuncts to levodopa/carbidopa therapy for patients with PD who exhibit motor fluctuations.
Rasagiline is also approved for
use as initial monotherapy. Selegiline is
available as capsules and orally disintegrating
tablets (ODT), and rasagiline
is available in tablet form. Pharmacists
and their patients should be aware of
potential dietary concerns and interactions
between MAO-B inhibitors and
other medications.
|
|
|
|
|
|
